| pubmed-article:1320276 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:1320276 | lifeskim:mentions | umls-concept:C0026336 | lld:lifeskim |
| pubmed-article:1320276 | lifeskim:mentions | umls-concept:C0018787 | lld:lifeskim |
| pubmed-article:1320276 | lifeskim:mentions | umls-concept:C0003639 | lld:lifeskim |
| pubmed-article:1320276 | lifeskim:mentions | umls-concept:C0025887 | lld:lifeskim |
| pubmed-article:1320276 | lifeskim:mentions | umls-concept:C0037492 | lld:lifeskim |
| pubmed-article:1320276 | lifeskim:mentions | umls-concept:C0005458 | lld:lifeskim |
| pubmed-article:1320276 | lifeskim:mentions | umls-concept:C0936012 | lld:lifeskim |
| pubmed-article:1320276 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:1320276 | pubmed:dateCreated | 1992-7-31 | lld:pubmed |
| pubmed-article:1320276 | pubmed:abstractText | A simulation model was developed to predict complex interaction between antiarrhythmic drugs and cardiac sodium channels. This model has four assumptions: (1) Vmax of the action potential is a linear indicator of available sodium channel conductance; (2) antiarrhythmic drugs block the channel by binding to a single common receptor site associated with the channel; (3) binding and dissociation rate constants differ for the three channel states: activated, inactivated and resting, and (4) both drug-free and drug-bound channels change states far more rapidly than binding and dissociation processes. Binding and dissociation rate constants for the three channel states were calculated from single cell experiments using guinea pig hearts. Vmax changes reflecting tonic and use-dependent sodium channel block in the presence of mexiletine and aprindine were simulated and compared with those obtained in the single cell experiments. The model predicted that 'tonic' Vmax inhibition would be enhanced, whereas 'use-dependent' ones would be attenuated after admixture of mexiletine with aprindine. The mechanisms would involve competitive interaction at the common receptor site. Single-cell experiments supported this prediction. We conclude that our simple two-drug binding model provides a useful tool to predict pharmacological interaction between class I antiarrhythmic drugs given in combination. | lld:pubmed |
| pubmed-article:1320276 | pubmed:language | eng | lld:pubmed |
| pubmed-article:1320276 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1320276 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:1320276 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1320276 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1320276 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1320276 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:1320276 | pubmed:issn | 0031-7012 | lld:pubmed |
| pubmed-article:1320276 | pubmed:author | pubmed-author:ToyamaJJ | lld:pubmed |
| pubmed-article:1320276 | pubmed:author | pubmed-author:KodamaII | lld:pubmed |
| pubmed-article:1320276 | pubmed:author | pubmed-author:KamiyaKK | lld:pubmed |
| pubmed-article:1320276 | pubmed:author | pubmed-author:HonjoHH | lld:pubmed |
| pubmed-article:1320276 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:1320276 | pubmed:volume | 44 | lld:pubmed |
| pubmed-article:1320276 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:1320276 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:1320276 | pubmed:pagination | 260-8 | lld:pubmed |
| pubmed-article:1320276 | pubmed:dateRevised | 2003-11-14 | lld:pubmed |
| pubmed-article:1320276 | pubmed:meshHeading | pubmed-meshheading:1320276-... | lld:pubmed |
| pubmed-article:1320276 | pubmed:meshHeading | pubmed-meshheading:1320276-... | lld:pubmed |
| pubmed-article:1320276 | pubmed:meshHeading | pubmed-meshheading:1320276-... | lld:pubmed |
| pubmed-article:1320276 | pubmed:meshHeading | pubmed-meshheading:1320276-... | lld:pubmed |
| pubmed-article:1320276 | pubmed:meshHeading | pubmed-meshheading:1320276-... | lld:pubmed |
| pubmed-article:1320276 | pubmed:meshHeading | pubmed-meshheading:1320276-... | lld:pubmed |
| pubmed-article:1320276 | pubmed:meshHeading | pubmed-meshheading:1320276-... | lld:pubmed |
| pubmed-article:1320276 | pubmed:meshHeading | pubmed-meshheading:1320276-... | lld:pubmed |
| pubmed-article:1320276 | pubmed:meshHeading | pubmed-meshheading:1320276-... | lld:pubmed |
| pubmed-article:1320276 | pubmed:meshHeading | pubmed-meshheading:1320276-... | lld:pubmed |
| pubmed-article:1320276 | pubmed:meshHeading | pubmed-meshheading:1320276-... | lld:pubmed |
| pubmed-article:1320276 | pubmed:meshHeading | pubmed-meshheading:1320276-... | lld:pubmed |
| pubmed-article:1320276 | pubmed:year | 1992 | lld:pubmed |
| pubmed-article:1320276 | pubmed:articleTitle | A model analysis for competitive binding of mexiletine and aprindine to the cardiac sodium channel. | lld:pubmed |
| pubmed-article:1320276 | pubmed:affiliation | Department of Circulation and Respiration, Nagoya University, Japan. | lld:pubmed |
| pubmed-article:1320276 | pubmed:publicationType | Journal Article | lld:pubmed |
